Parkinson's Disease - References

References

Citations

1. DeLong MR, Juncos JL (2005). Parkinson's disease and other movement disorders. In DL Kasper et al., eds., Harrison's Principles of Internal Medicine, 16th ed., pp. 2406–2418. New York: McGraw-Hill.

   Related Articles

   • Parkinson's Disease - Treatment Overview
   • Parkinson's Disease - Topic Overview

   » More resources Articles

2. Clarke CE, Guttman M (2002). Dopamine agonist monotherapy in Parkinson's disease. Lancet, 360(9347): 1767–1769.

3. Clarke C, Moore AP (2005). Parkinson's disease. Clinical Evidence (14): 1652–1668.

4. Korczyn AD, Nussbaum M (2002). Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs, 62(5): 775–786.

5. Stacy M, Factor S (2004). Rapid treatment of "off" episodes: Will this change Parkinson's disease therapy? Neurology, 62(6, Suppl 4): S1–S2.

6. Miyasaki JM, et al. (2002). Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. Neurology, 58(1): 11–17.

7. Hobson DE, et al. (2002). Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease. JAMA, 287(4): 455–463.

8. Samii A, et al. (2004). Parkinson's disease. Lancet, 363(9423): 1783–1793.

9. Shults CW, et al. (2002). Effects of coenzyme Q10 in early Parkinson disease. Archives of Neurology, 59(10): 1541–1550.

10. Storch A, et al. (2007). Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson's disease. Archives of Neurology, 64(7): 938–944.

Other Works Consulted

• Deuschl G, et al. (2006). A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine, 355(9): 896–908.

• Juncos JL, DeLong MR (2005). Parkinson disease and other movement disorders. In DC Dale, DD Federman, eds., ACP Medicine, section 11, chap. 15. New York: WebMD.

• Miyasaki JM, et al. (2006). Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 996–1002.

• Pahwa R, et al. (2006). Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 983–985.

• Siderowf A, Stern M (2003). Update on Parkinson disease. Annals of Internal Medicine, 138(8): 651–658.

• Suchowersky O, et al. (2006). Practice parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 968–975.

• Suchowersky O, et al. (2006). Practice parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 976–982.